Background: The use of benzodiazepines in relation to cognitive decline remains an area of controversy in aging populations. Objective: This study aims to evaluate the risk of cognitive impairment-not dementia (CIND), Alzheimer disease (AD), and all-cause dementia with benzodiazepine use. The effect modification by sex was also investigated. Methods: Data come from the Canadian Study of Health and Aging, a 10-year multicentric study involving 10 263 participants randomly selected, 65 years and older, living in the community and in institutions. Current exposure to benzodiazepines was assessed in a face-to-face interview or self-reported in a questionnaire. Cox proportional hazard regression models, using age as time scale, were conducted to estimate hazard ratios, with adjustment for sex, education, smoking, alcohol intake, depression, physical activity, nonsteroidal anti-inflammatory drug use, and vascular comorbidities. Results: Data sets included 5281 participants for dementia as the outcome, 5015 for AD, and 4187 for CIND. Compared with nonusers, current use of benzodiazepines was associated with an increased risk of CIND (hazard ratio = 1.36; 95% CI = 1.08-1.72) in the simplest model. Results remained similar in the fully adjusted model (hazard ratio = 1.32; 95% CI = 1.04-1.68). There was no association between benzodiazepine use and the risk of dementia or AD. All these effects were similar between men and women. Conclusion and Relevance: Benzodiazepine use in older people from the general population is related to subsequent occurrence of cognitive dysfunction but not implicated in the pathogenesis of dementia or AD. Caution should be exercised when prescribing benzodiazepines to preserve global cognitive function.
Introduction
Despite many concerns, benzodiazepines still remain one of the most commonly prescribed psychotropic medications in people aged between 65 and 80 years, 1 with a prevalence of use of 6.1% in men and 10.8% in women, respectively. 2 Given the known neurocognitive adverse effects of benzodiazepines, older populations could be more at risk of showing precocious cognitive dysfunction or dementia with time. 3 To date, studies investigating the associations between benzodiazepine use and dementia have shown conflicting results. Some studies found an increased risk of dementia, [4] [5] [6] [7] [8] whereas others were rather inconclusive. [9] [10] [11] A clinical review reported that the associations were strongest for longer-acting benzodiazepines, longer durations of use, and earlier rather than later exposure. 12 An increasing number of longitudinal studies have focused on the relationship between benzodiazepine use and cognitive decline in older people. These studies generally showed poorer cognitive performance among benzodiazepine users. 5, 8, [13] [14] [15] [16] Most of these studies assessed cognitive function on the basis of scores obtained with the use of global screening instruments and neuropsychological test batteries. However, these tests are usually designed to screen for all-cause dementia or specific cognitive domains rather than mild cognitive impairment (MCI) or dysfunction. Furthermore, very few studies evaluated the differential effect of benzodiazepine use in men and women.
The National Institute on Aging and the Alzheimer's Association workgroups 17 have recommended that research efforts be directed toward the study of preclinical Alzheimer disease (AD) in order to intervene in the future at an earlier stage of the disease when some disease-modifying therapies may be efficacious. The concept of cognitive impairmentno dementia (CIND) has been defined in the Canadian Study of Health and Aging (CSHA) as a heterogeneous clinical entity encompassing cognitive impairments that could evolve into various psychiatric and neurological diseases, including dementia. 18 In contrast to MCI case definitions, the CIND classification does not exclude persons on the basis of the etiology of cognitive impairment such as preexisting medical, neurological, psychiatric, or pharmacological conditions. This broadening of the CIND definition was found to increase the prediction of dementia compared with other classifications of MCI. 19 In this latter study, about 30% of CIND participants converted to dementia over a 5-year period in CSHA. In the United States, the incidence of CIND was estimated to be 60.4 cases per 1000 person-years, almost double that of all-cause dementia, and 120.3 cases per 1000 person-years progressed from CIND to dementia. Identifying risk factors upstream of the disease would provide better primary prevention of all-cause dementia and AD. 20 The aim of the current study is to examine the association between benzodiazepine use and the incidence of CIND, AD, and all-cause dementia, using data from the CSHA. The modifying effect of sex on these relationships was also investigated.
Methods

Participants
The CSHA is a 3-phase, 10-year, national, multicenter longitudinal study whose purposes were to determine the prevalence, incidence, and risk factors of all-cause dementia and subtypes in Canadians 65 years of age and older. 21 Of the 10 263 participants selected, 9008 were residing in the community and 1255, in institutions. The baseline phase of CSHA (CSHA-1) took place in 1991-1992. Subsequent evaluations were conducted in 1996-1997 (CSHA-2) and 2001-2002 (CSHA-3). The study was approved at each phase by the ethics review committees of the 18 participating research centers across Canada and the coordinating center in Ottawa. Data were collected from representative samples of men and women in 36 urban and surrounding rural areas covering all provinces of the country.
Cognitive Function
Community-dwelling individuals participated in a screening interview about several aspects of their general health, after which they were administered the 100-point Modified Mini-Mental State Examination (3MS), a validated screening test for dementia. 22 All participants screening positive for dementia (3MS ≤ 77), a random sample of participants who screened negative, and all participants living in institutions were invited to attend an extensive clinical evaluation. During this evaluation, a nurse readministered the 3MS and gathered information on the participant's medical and family history. Next, the participant met with a physician who reviewed the information collected by the nurse before performing a standardized physical and neurological evaluation. Finally, the participant screening positive at the first 3MS assessment and deemed testable according to a score of ≥50 was administered a battery of neuropsychological tests, the results of which were interpreted by a neuropsychologist. The participant with a 3MS score of <50 was evaluated by the nurse and the physician exclusively. Preliminary diagnoses were made independently by the physician and the neuropsychologist. The final diagnosis was made after a case conference during which a consensus was reached. 21 The diagnosis of all-cause dementia was made according to the revised third edition of the Diagnosis and Statistical Manual of Mental Disorders (DSM-III-R) criteria. For AD, the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria were adopted. DSM-III-R and the International Classification of Diseases, 10th revision (ICD-10) criteria served to make a diagnosis of CIND. Participants screening negative or clinically diagnosed not cognitively impaired were asked to complete a self-administered risk factor questionnaire that covered different aspects of sociodemographic characteristics, occupational and environmental exposures, lifestyle, medical and family history, and other specific potential risk factors for dementia.
At the first follow-up (CSHA-2), participants who could be reached were invited to take part to a similar 2-stage diagnostic process as in CSHA-1. 21 Two diagnoses were made for each participant during the case conference: the first using the same criteria as in CSHA-1 and the second using criteria from the fourth edition of the DSM (DSM-IV).
The study methods and the diagnostic criteria of the second follow-up (CSHA-3) were similar to those used in CSHA-2, although the 3MS cut-point was set at 89/90 for the screening of CIND rather than dementia. 21 For the purpose of this study, we used DSM-IV criteria in CSHA-2 and CSHA-3.
Assessment of Benzodiazepine Use
Benzodiazepine exposure was measured at baseline using data collected from either the risk factor questionnaire or the clinical evaluation. In the risk factor questionnaire, participants were asked to list all medications they were currently taking for any conditions, to fill in the name of medications on pill bottles or containers, and to include both prescription and nonprescription medications. During the clinical examination, participants were asked by the nurse to list all their current medications with or without prescription. These medications were then coded using the World Health Organization's Anatomical Therapeutic Chemical classification. 23 For the purpose of this study, we considered all benzodiazepines available at CSHA baseline.
Covariates
In addition to age, sex, and education, we controlled for a number of factors that could be related to benzodiazepine use and dementia. These variables were measured at baseline using either the risk factor questionnaire or the clinical evaluation. Among variables dichotomized, we had residence status (community/institution), smoking status (nonsmoker/ever regular smoker), alcohol intake (ever been drinking regularly (at least 1 alcoholic drink a week or not), and history of specific comorbidities, including depression (yes/no), hypertension (high blood pressure or use of hypertensive drugs; yes/no), diabetes mellitus (yes/no), and stroke (yes/no). Regular physical activity was categorized as none, low, moderate, and high. 24 Nonsteroidal antiinflammatory drugs (NSAIDs) were coded as user or nonuser. 25 Education was treated as a continuous variable.
Statistical Analyses
We compared baseline characteristics by benzodiazepine exposure using the Student t test for continuous variables and χ 2 test for categorical variables. Hazard ratios with 95% CIs were calculated using the Cox proportional hazards model, with delayed entry and age as the time scale, to evaluate the associations between the use of benzodiazepines and 3 different outcomes: CIND, AD, and all-cause dementia. Because onset of disease occurred between 2 subsequent evaluations, time to event on the age scale was interval censored between the 2 evaluations. Participants who remained cognitively normal or died were censored at the time of the last evaluation. The proportional hazards assumptions were tested and found to be satisfied. The linearity assumption for continuous variables was found to be satisfied.
The association of benzodiazepine use with the incidence of all-cause dementia and AD was evaluated in 2 other data sets (n = 5281 for dementia and 5015 for AD, respectively; Figure 1 ). These data sets included, at baseline, participants without cognitive impairment according to the screening test or dementia according to the clinical evaluation. When AD was the outcome, participants who developed a dementia other than AD were excluded from the data set. The association of benzodiazepine use with the incidence of CIND was evaluated in a data set (n = 4187) including at baseline participants not cognitively impaired according to the clinical evaluation or the screening test if there was no clinical evaluation. Participants who were CIND at baseline or who developed all-cause dementia during follow-up without being diagnosed with CIND before were excluded.
The models were adjusted for potential confounders identified from the literature as risk factors both for benzodiazepine use and for dementia. Three models were built for each outcome: a model including only age as time scale (model 1), a model additionally adjusted for sex and education (model 2), and finally, a model additionally adjusted for smoking, alcohol intake, physical activity, depression, hypertension, myocardial infarction, stroke, diabetes, and NSAID use (model 3). Multiple imputation using chained equations was performed for models 2 and 3. Thirty imputed data sets were created; this number corresponds to the percentage of incomplete cases (30%). The 3MS score was not entered in our models to adjust for baseline cognitive status, because the 3MS was part of the diagnostic process. Finally, to investigate the modification effect of sex, an interaction term between benzodiazepine use and sex was entered in model 2 of each outcome. Analyses were performed using SAS software, version 9.4 (SAS Institute, Inc, Cary, NC).
Results
Of the 10 263 participants at baseline, 3005 were excluded from the analysis because they refused the clinical examination at CSHA-1 despite a positive screening (n = 508), prevalent dementia (n = 1132), or the absence of information on their use of benzodiazepines (n = 1365). Of the remaining eligible participants (n = 7258), 1977 (27.2%) could not be included owing to death before CSHA-2 (n = 1702) or refusals or absence of follow-up for unknown reasons (n = 275). When compared with excluded participants, those included in the final sample were significantly younger (74 vs 79 years) and more educated (10.6 vs 9.3 years) and were using more benzodiazepines (12% vs 9%; all P values < 0.001). There was no difference according to sex. Of the 5281 participants included in the study sample, 477 (9.0%) were taking benzodiazepines at baseline. The proportion of users increased with age and was higher among women (10.8% vs 6.3% among men) and in those living in institutions (25.8% vs 8.3% in the community). The mean followup time was 5.4 years (range, 3.4-11.4 years).
Baseline characteristics of participants are summarized in Table 1 . Compared with nonusers, benzodiazepine users were, on average, slightly older (75.1 vs 74.1 years), included more women (72.8% vs 59.8%), were less educated (9.6 vs 10.8 years), comprised fewer community-dwelling individuals (88.3% vs 96.7%), and included fewer smokers and alcohol consumers. Benzodiazepine users were also more depressed (20.8% vs 6.5%); showed more vascular comorbidities, including cardiac infarction, hypertension, and stroke; were taking more NSAID medications (58.9 % vs 52.7%); were less active; and had a lower mean 3MS score at baseline (86.4 vs 89.5).
In the simplest model, the use of benzodiazepines was significantly associated with an increased risk of CIND (hazard ratio = 1.36, 95% CI = 1.08-1.72; Table 2 ). The risk estimates remained similar and significant in the semiadjusted and fully adjusted models (hazard ratios = 1.38 [95% CI = 1.10-1.75] and 1.32 [95% CI = 1.04-1.68], respectively).
The use of benzodiazepines was not associated with the incidence of either all-cause dementia or AD (Table 2) . Finally, no effect modification by sex was observed for each outcome (P values for interaction terms of 0.40, 0.51, and 0.92 for CIND, AD, and dementia, respectively), meaning that the association between benzodiazepine use and these specific outcomes did not differ according to sex.
Discussion
Using data from a large-scale population study representative of the Canadian older population, we found a significantly higher age-, sex-, and education-adjusted risk of CIND associated with benzodiazepine use. The association remained significant after adjustment for several potential confounders, including smoking, alcohol intake, physical activity, depression, myocardial infarction, hypertension, stroke, diabetes, and NSAID drugs. No association was found for allcause dementia or AD. There was no difference in these relationships between men and women. Our results are based on a large representative sample of older people followed for more than a decade. The strengths of this study include the random selection of participants, high response rate at the 3 phases, and careful standardization of screening and clinical evaluations.
The comparison of our results with those of the literature is not straightforward. Cognitive decline is frequently measured according to cognitive tests rather than according to a clinical diagnosis made by the physician and/or the neuropsychologist case. Gallacher et al, 5 however, used CIND as an outcome in a prospective study of 1134 men living in the United Kingdom with a mean age of 56 years at baseline. A nonsignificant, protective association between benzodiazepine use and CIND was found after a 22-year follow-up. These findings are difficult to interpret given that the risk for dementia in benzodiazepine users in this study was significantly increased by approximately 3-fold, and that cognitive impairment is usually considered as part of the natural history of dementia. Another study investigated CIND and dementia as a joint outcome (59 CIND and 14 participants with dementia of the 73 incident cases) in a small subsample of 510 community-dwelling women participating in the first 2 phases of CSHA. 26 In this study, the use of benzodiazepines measured using the prescription database was not associated with the joint outcome.
When we examined the effect of benzodiazepine use on the incidence of all-cause dementia and AD, we did not find any significant association. Our findings are consistent with earlier reports from longitudinal 11 or case-control studies, 10, 27 which concluded that benzodiazepine use does not seem to have an effect on the incidence of dementia and AD. The effect estimates in these studies were similar to ours. The results of the current study are also in line with those of Hogan et al, 28 who restricted their study sample to CSHA-1 participants clinically (n = 2914); the use of benzodiazepines was not associated with the 5-year incidence of dementia. In contrast to our results, Gallacher et al 5 observed an increased risk of dementia associated with the use of benzodiazepines. Gray et al 8 also found an increased risk of dementia with minimal exposure to benzodiazepines but not with the highest levels. Using Quebec medico-administrative database of people living in the community, Billioti de Gage et al 7 reported a fairly good association between cumulative lifetime benzodiazepine dose and the risk of AD, but results were not adjusted for education, a well-known protective factor for AD. To date, we still know little of the biological and cerebral modifications that occur during chronic administration of benzodiazepines. Several structural alterations in the brain could be involved in the mechanisms by which benzodiazepines might accelerate cognitive decline. First, there is the possibility of a decrease in the number of benzodiazepine receptors 29, 30 ; second, a reduction in the number of chloride channels in the GABA A receptor complex 29 ; and finally, alterations in synaptic plasticity and recognition memory. 31 Several limitations in our study should be taken into consideration. First, of all eligible participants for our analyses on dementia, 1977 (27.2%) were excluded because of refusals or missing before a first follow-up. These individuals were older, less educated, and were using more benzodiazepines, which suggests that the selection bias, if any, would tend to underestimate the associations. Second, information on benzodiazepine exposure was derived mostly from a self-reported questionnaire without any additional validation. We had no information on the pattern of use of benzodiazepines, such as duration, dosage, intermittent exposure, and exposure to multiple benzodiazepines. The exposure was ascertained only once during a short window of time. It is possible that this does not reflect long-term practices. The resulting potential information bias, although nondifferential, may have underestimated our estimates. Third, the 3MS score has been validated for the screening for dementia and might be less sensitive to detect subtle cognitive dysfunction, as is the case in CIND. Individuals with CIND might have been missed when the 3MS cutoff was set at 77/78. This may have led to a misclassification error. This nondifferential error might have underestimated our risk estimates in the CIND analysis. Fourth, as with many secondary analyses of data, we were limited by the data that were collected and were not able to control for all potential confounders, such as the presence of anxiety, head trauma, anticholinergic exposure, or sleep disorders. Furthermore, other potential confounders considered in the analyses such as hypertension, diabetes, and NSAID exposure may have changed over time. Residual confounding is thus possible.
From the clinical practice point of view, although our findings do not support clinical decision making, it remains important to know that older adults with CIND, which is close in definition to MCI, may present with behavioral and psychological symptoms of dementia leading to a benzodiazepine prescription. 32 Reverse causality is thus possible. It is also of note that current guidelines for geriatric care 33, 34 do not recommend the use of benzodiazepines as a first-line treatment for insomnia, agitation, or delirium. Successful deprescribing interventions for benzodiazepines in older persons have recently been reported. 35, 36 
Conclusion and Relevance
On the basis of our study and despite possible limitations, we conclude that benzodiazepine use may contribute to an increased risk of cognitive decline in the community-dwelling older population. However, our results did not reinforce the suspicion of an increased risk of dementia, specifically AD, among benzodiazepine users. It rather seems that the effects of benzodiazepines on cognitive function could worsen the clinical expression of early dementia than triggering the onset of this disease. Caution should be exercised when prescribing benzodiazepines to preserve global cognitive function. Future research should focus on explaining the way in which benzodiazepines possibly induce CIND, with a better assessment of the exposure, and finding sustainable ways to optimize or decrease the use of these medications in the older population.
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